Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott Japan and Eisai have agreed to launch Humira (adalimumab) Prefilled Syringe 20mg/0.4ml as a treatment for polyarticular juvenile idiopathic arthritis (JIA) patients with low body weight.
Subscribe to our email newsletter
The new 20mg prefilled syringe is a new formulation of Humira that was developed as a treatment for JIA patients with a body weight of between 15kg and 30kg.
In July, 2011, the Japanese Ministry of Health, Labour and Welfare has approved the marketing and manufacturing approval for Humira Prefilled Syringe 20mg/0.4ml.
Abbott Japan is the marketing and manufacturing authorization holder for Humira, while Eisai is responsible for the distribution of the product in Japan.